Pub Date : 2026-01-01Epub Date: 2025-11-11DOI: 10.1016/j.leukres.2025.108133
Shulan Tian , Hanyin Wang , Sameer A. Parikh , Yuanhang Liu , Helen Jin-Lee , Erik Jessen , Eric W. Klee , Yucai Wang , Fan Leng , Min Shi , Cinthya Zepeda-Mendoza , Rong He , Saad J. Kenderian , Linda B. Baughn , Daniel L. Van Dyke , Paul J. Hampel , Neil E. Kay , Esteban Braggio , Susan L. Slager , Huihuang Yan , Wei Ding
Richter transformation (RT) represents the development of an aggressive lymphoma in chronic lymphocytic leukemia (CLL). Patients with RT and relapsed CLL have poor outcomes. Yet, the molecular differences between the two entities have not been fully explored. In this pilot study, we conducted RNA-seq and targeted panel sequencing of nodal tissues from 12 patients, including seven with RT and five with CLL. Analysis of RNA-seq data revealed two major clusters, with five RT in cluster C1 and the remaining two RT and all five CLL in C2. Within C2, one of the CLL ultimately developed RT; it showed more similarity to the two RT than to the other CLL in expression profile, suggesting the presence of expression signature for RT prior to the clinical diagnosis. In addition, differentially expressed genes, the majority of which showed higher expression in C1 relative to C2, were enriched in pathways known to be important for CLL pathogenesis or transformation. Deconvolution of the bulk RNA-seq data revealed major differences in cellular composition between the two clusters, notably tumor B cells, macrophages M1, and CD8 + T cells. Furthermore, by targeted sequencing, we identified 51 genes that carried recurrent copy number alterations (CNAs) preferentially occurring in either cluster. Over 80 % of these CNAs occurred in C2, mainly gains of 17q12q25 in CLL. Patients in C1 had shorter overall survival (median 11 months) compared to those in C2 (median 36 months). Together, our findings highlight noticeable differences in transcriptomic and genomic alterations between CLL versus RT.
{"title":"Genomic profiling reveals molecular heterogeneity in patients with Richter transformation (RT) and chronic lymphocytic leukemia (CLL)","authors":"Shulan Tian , Hanyin Wang , Sameer A. Parikh , Yuanhang Liu , Helen Jin-Lee , Erik Jessen , Eric W. Klee , Yucai Wang , Fan Leng , Min Shi , Cinthya Zepeda-Mendoza , Rong He , Saad J. Kenderian , Linda B. Baughn , Daniel L. Van Dyke , Paul J. Hampel , Neil E. Kay , Esteban Braggio , Susan L. Slager , Huihuang Yan , Wei Ding","doi":"10.1016/j.leukres.2025.108133","DOIUrl":"10.1016/j.leukres.2025.108133","url":null,"abstract":"<div><div>Richter transformation (RT) represents the development of an aggressive lymphoma in chronic lymphocytic leukemia (CLL). Patients with RT and relapsed CLL have poor outcomes. Yet, the molecular differences between the two entities have not been fully explored. In this pilot study, we conducted RNA-seq and targeted panel sequencing of nodal tissues from 12 patients, including seven with RT and five with CLL. Analysis of RNA-seq data revealed two major clusters, with five RT in cluster C1 and the remaining two RT and all five CLL in C2. Within C2, one of the CLL ultimately developed RT; it showed more similarity to the two RT than to the other CLL in expression profile, suggesting the presence of expression signature for RT prior to the clinical diagnosis. In addition, differentially expressed genes, the majority of which showed higher expression in C1 relative to C2, were enriched in pathways known to be important for CLL pathogenesis or transformation. Deconvolution of the bulk RNA-seq data revealed major differences in cellular composition between the two clusters, notably tumor B cells, macrophages M1, and CD8 + T cells. Furthermore, by targeted sequencing, we identified 51 genes that carried recurrent copy number alterations (CNAs) preferentially occurring in either cluster. Over 80 % of these CNAs occurred in C2, mainly gains of 17q12q25 in CLL. Patients in C1 had shorter overall survival (median 11 months) compared to those in C2 (median 36 months). Together, our findings highlight noticeable differences in transcriptomic and genomic alterations between CLL versus RT.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"160 ","pages":"Article 108133"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145537567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01Epub Date: 2025-11-28DOI: 10.1016/j.leukres.2025.108144
Cameron J. Hunter , Andrew Chou , Heidi Roeder , William Eighmy , Jan Philipp Bewersdorf , Lourdes Mendez , Maximilian Stahl , Nikolai A. Podoltsev , Amer M. Zeidan , Rory M. Shallis
Voriconazole has been a standard antifungal prophylactic (AFP) agent for patients with acute myeloid leukemia (AML) during neutropenia. However, its use is complicated by side-effects including transaminase elevations, visual disturbances, and significant drug-drug interactions (DDIs). Isavuconazole is an AFP agent with a more attractive side-effect profile. In a retrospective analysis we compared rates of complications necessitating AFP withdrawal between patients with AML who initially started on isavuconazole (n = 63) or voriconazole (n = 215), and of invasive fungal infection (IFI) and median overall survival (OS) between patients who used only isavuconazole (n = 41) or voriconazole (n = 90). Voriconazole was associated with higher rates of AFP discontinuation due to transaminase elevations (p = 0.019), visual disturbances (p = 0.002), or DDIs (p = 0.002), while isavuconazole was more frequently discontinued due to coverage denial/high cost (p < 0.0001). Rates/classification of IFI, breakthrough IFI (bIFI) and IFI-free survival (IFI-FS) were comparable between azoles in both analyses. Isavuconazole is an effective AFP agent with a superior side-effect profile and should thus be considered as a promising AFP option for patients with AML.
{"title":"Isavuconazole provides effective and tolerable antifungal prophylaxis for patients with acute myeloid leukemia","authors":"Cameron J. Hunter , Andrew Chou , Heidi Roeder , William Eighmy , Jan Philipp Bewersdorf , Lourdes Mendez , Maximilian Stahl , Nikolai A. Podoltsev , Amer M. Zeidan , Rory M. Shallis","doi":"10.1016/j.leukres.2025.108144","DOIUrl":"10.1016/j.leukres.2025.108144","url":null,"abstract":"<div><div>Voriconazole has been a standard antifungal prophylactic (AFP) agent for patients with acute myeloid leukemia (AML) during neutropenia. However, its use is complicated by side-effects including transaminase elevations, visual disturbances, and significant drug-drug interactions (DDIs). Isavuconazole is an AFP agent with a more attractive side-effect profile. In a retrospective analysis we compared rates of complications necessitating AFP withdrawal between patients with AML who initially started on isavuconazole (n = 63) or voriconazole (n = 215), and of invasive fungal infection (IFI) and median overall survival (OS) between patients who used only isavuconazole (n = 41) or voriconazole (n = 90). Voriconazole was associated with higher rates of AFP discontinuation due to transaminase elevations (p = 0.019), visual disturbances (p = 0.002), or DDIs (p = 0.002), while isavuconazole was more frequently discontinued due to coverage denial/high cost (p < 0.0001). Rates/classification of IFI, breakthrough IFI (bIFI) and IFI-free survival (IFI-FS) were comparable between azoles in both analyses. Isavuconazole is an effective AFP agent with a superior side-effect profile and should thus be considered as a promising AFP option for patients with AML.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"160 ","pages":"Article 108144"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145715027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01Epub Date: 2025-12-19DOI: 10.1016/j.leukres.2025.108149
Margarida Coucelo , Claudia Sargas , Rosa Ayala , María J. Larráyoz , María Carmen Chillón , Elena Soria , Cristina Bilbao , Esther Prados de la Torre , Maria Luis Amorim , Alberto Mirales , Antonia Cionfrini , Ana T. Simões , Ana C. Oliveira , Rebeca Rodríguez-Veiga , Pilar Lloret-Madrid , Yolanda Mendizábal , Carmen Botella , Teresa Bernal , Juan Bergua , Lorenzo Algarra , Eva Barragán
The rapid and accurate laboratory identification of targetable therapeutic genes, together with the implementation of measurable residual disease (MRD) based decision is essential for optimal clinical management in acute myeloid leukemia (AML). The PETHEMA (Programa Español de Tratamientos en Hematología) cooperative group comprises nine laboratories that perform centralized molecular studies by conventional PCR and Real-time quantitative PCR (RT-qPCR) for AML patients. With the aim to validate laboratories performances, we conducted three rounds of interlaboratory cross validation (ICV) for the quantification of CBFB::MYH11, RUNX1::RUNX1T1 and NPM1 and one round to determine the mutational status of NPM1, FLT3 (ITD and TKD2) IDH1 and IDH2. For RT-qPCR a total of 19 samples were tested and only 3 (15.8 %) failed to achieve 100 % concordance, corresponding to samples with low target gene mean ratios (ICV1-S4, ICV2-S1, ICV2-S6). For mutation detection in a total of 227 returned results, concordance rate ranged from 95 % to 100 %. FLT3-ITD and NPM1 mutation detection had 100 % concordant results. One false negative was reported for IDH2- R140 mutation and 4 false positives were detected: 2 FLT3-TKD2 and 2 IDH1-R132, likely reflecting differences in assay sensitivity. Overall, the results were highly satisfactory, particularly regarding MRD assessment, and highlighted key points for improvement, especially in baseline detection of FLT3-TKD2 and IDH1 mutations. This study represents the first collaborative initiative to evaluate performance of AML molecular targets within a laboratory network and underscores the importance of regular exercises to monitor performance, identify and resolve technical or interpretive discrepancies to ultimately ensure accurate clinical decision-making.
快速准确的实验室鉴定靶向治疗基因,以及基于可测量残留病(MRD)的决策的实施,对于急性髓性白血病(AML)的最佳临床管理至关重要。PETHEMA (Programa Español de Tratamientos en Hematología)合作小组由9个实验室组成,通过传统PCR和实时定量PCR (RT-qPCR)对AML患者进行集中的分子研究。为了验证实验室性能,我们进行了三轮实验室间交叉验证(ICV)来量化CBFB::MYH11、RUNX1::RUNX1T1和NPM1,并进行了一轮实验室间交叉验证(ICV)来确定NPM1、FLT3 (ITD和TKD2) IDH1和IDH2的突变状态。RT-qPCR共检测了19个样本,只有3个(15.8 %)未能达到100 %的一致性,对应于低靶基因平均比率的样本(ICV1-S4, ICV2-S1, ICV2-S6)。对于227个返回结果的突变检测,一致性率从95 %到100 %不等。FLT3-ITD与NPM1突变检测结果吻合度为100% %。报告了1例IDH2- R140突变假阴性和4例假阳性:2例FLT3-TKD2和2例IDH1-R132,可能反映了测定敏感性的差异。总体而言,结果非常令人满意,特别是在MRD评估方面,并强调了改进的关键点,特别是在FLT3-TKD2和IDH1突变的基线检测方面。该研究是首次在实验室网络中评估AML分子靶点表现的合作倡议,并强调了定期锻炼以监测表现、识别和解决技术或解释差异的重要性,最终确保准确的临床决策。
{"title":"Interlaboratory cross validation of acute myeloid leukemia fusion genes and mutational targets detected by PCR: Performance of PETHEMA central laboratories","authors":"Margarida Coucelo , Claudia Sargas , Rosa Ayala , María J. Larráyoz , María Carmen Chillón , Elena Soria , Cristina Bilbao , Esther Prados de la Torre , Maria Luis Amorim , Alberto Mirales , Antonia Cionfrini , Ana T. Simões , Ana C. Oliveira , Rebeca Rodríguez-Veiga , Pilar Lloret-Madrid , Yolanda Mendizábal , Carmen Botella , Teresa Bernal , Juan Bergua , Lorenzo Algarra , Eva Barragán","doi":"10.1016/j.leukres.2025.108149","DOIUrl":"10.1016/j.leukres.2025.108149","url":null,"abstract":"<div><div>The rapid and accurate laboratory identification of targetable therapeutic genes, together with the implementation of measurable residual disease (MRD) based decision is essential for optimal clinical management in acute myeloid leukemia (AML). The PETHEMA (Programa Español de Tratamientos en Hematología) cooperative group comprises nine laboratories that perform centralized molecular studies by conventional PCR and Real-time quantitative PCR (RT-qPCR) for AML patients. With the aim to validate laboratories performances, we conducted three rounds of interlaboratory cross validation (ICV) for the quantification of <em>CBFB::MYH11, RUNX1::RUNX1T1</em> and <em>NPM1</em> and one round to determine the mutational status of <em>NPM1</em>, <em>FLT3</em> (ITD and TKD2) <em>IDH1</em> and <em>IDH2</em>. For RT-qPCR a total of 19 samples were tested and only 3 (15.8 %) failed to achieve 100 % concordance, corresponding to samples with low target gene mean ratios (ICV1-S4, ICV2-S1, ICV2-S6). For mutation detection in a total of 227 returned results, concordance rate ranged from 95 % to 100 %. <em>FLT3</em>-ITD and <em>NPM1</em> mutation detection had 100 % concordant results. One false negative was reported for <em>IDH2</em>- R140 mutation and 4 false positives were detected: 2 <em>FLT3</em>-TKD2 and 2 <em>IDH1</em>-R132, likely reflecting differences in assay sensitivity. Overall, the results were highly satisfactory, particularly regarding MRD assessment, and highlighted key points for improvement, especially in baseline detection of <em>FLT3</em>-TKD2 and <em>IDH1</em> mutations. This study represents the first collaborative initiative to evaluate performance of AML molecular targets within a laboratory network and underscores the importance of regular exercises to monitor performance, identify and resolve technical or interpretive discrepancies to ultimately ensure accurate clinical decision-making.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"160 ","pages":"Article 108149"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145827893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01Epub Date: 2025-12-12DOI: 10.1016/j.leukres.2025.108148
Min Zou, Bolin Wan, Jing Hu
Introduction
Relapsed or refractory acute lymphoblastic leukemia (R/R ALL) remains a major therapeutic challenge with poor long-term survival outcomes. Although checkpoint inhibitors targeting PD-1/PD-L1 have shown efficacy in other hematologic malignancies, their role in ALL has not been fully defined. Combination strategies integrating PD-1/PD-L1 blockade with chemotherapy or CAR-T cells may enhance anti-leukemic responses and overcome immune resistance.
Methods
In this multicenter, open-label Phase II trial, 168 patients with R/R ALL were randomized to receive either FLAG chemotherapy plus nivolumab (Group A), CD19-directed CAR-T cells plus atezolizumab (Group B), or FLAG alone (Control). The primary endpoint was progression-free survival (PFS); secondary outcomes included overall survival (OS), MRD negativity, and safety. Immune profiling assessed biomarkers like PD-L1, TIM-3, CD25 + , and cytokines.
Results
MRD negativity rates were significantly higher in experimental arms compared to control (Group A: 19.5 %; Group B: 27.8 %; Control: 3 %; p < 0.001). Median PFS was 7.7 months in Group A, 11.7 months in Group B, and 4.1 months in the control group (p < 0.001). Median OS was 10.75, 13.5, and 5.65 months, respectively (p < 0.001). Higher baseline PD-L1 expression was independently associated with improved survival (HR 0.90 per 10 % increase; p = 0.002). The addition of checkpoint inhibitors did not significantly increase severe toxicities, and infection rates were lower in experimental groups compared to control. The swimmer plot analysis demonstrated prolonged remission in MRD-negative patients.
Conclusion
Adding PD-1 or PD-L1 blockade to either chemotherapy or CAR-T therapy improved clinical outcomes without excess toxicity in R/R ALL.
{"title":"Efficacy and safety of PD-1/PD-L1 inhibitors in combination with chemotherapy or CAR-T cells for relapsed/refractory acute lymphoblastic leukemia: A multicenter phase ii trial","authors":"Min Zou, Bolin Wan, Jing Hu","doi":"10.1016/j.leukres.2025.108148","DOIUrl":"10.1016/j.leukres.2025.108148","url":null,"abstract":"<div><h3>Introduction</h3><div>Relapsed or refractory acute lymphoblastic leukemia (R/R ALL) remains a major therapeutic challenge with poor long-term survival outcomes. Although checkpoint inhibitors targeting PD-1/PD-L1 have shown efficacy in other hematologic malignancies, their role in ALL has not been fully defined. Combination strategies integrating PD-1/PD-L1 blockade with chemotherapy or CAR-T cells may enhance anti-leukemic responses and overcome immune resistance.</div></div><div><h3>Methods</h3><div>In this multicenter, open-label Phase II trial, 168 patients with R/R ALL were randomized to receive either FLAG chemotherapy plus nivolumab (Group A), CD19-directed CAR-T cells plus atezolizumab (Group B), or FLAG alone (Control). The primary endpoint was progression-free survival (PFS); secondary outcomes included overall survival (OS), MRD negativity, and safety. Immune profiling assessed biomarkers like PD-L1, TIM-3, CD25 + , and cytokines.</div></div><div><h3>Results</h3><div>MRD negativity rates were significantly higher in experimental arms compared to control (Group A: 19.5 %; Group B: 27.8 %; Control: 3 %; p < 0.001). Median PFS was 7.7 months in Group A, 11.7 months in Group B, and 4.1 months in the control group (p < 0.001). Median OS was 10.75, 13.5, and 5.65 months, respectively (p < 0.001). Higher baseline PD-L1 expression was independently associated with improved survival (HR 0.90 per 10 % increase; p = 0.002). The addition of checkpoint inhibitors did not significantly increase severe toxicities, and infection rates were lower in experimental groups compared to control. The swimmer plot analysis demonstrated prolonged remission in MRD-negative patients.</div></div><div><h3>Conclusion</h3><div>Adding PD-1 or PD-L1 blockade to either chemotherapy or CAR-T therapy improved clinical outcomes without excess toxicity in R/R ALL.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"160 ","pages":"Article 108148"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145839660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01Epub Date: 2025-12-19DOI: 10.1016/j.leukres.2025.108151
Carmen Stanganelli, Juana Cabrera, Andrea Bender, Evangelina Agriello, Davi Coe Torres, Gerson Moura Ferreira, Maria Paula Mota dos Santos, Eliana Saul Furquim Werneck Abdelhay, Irma Slavutsky
{"title":"Double IGHV rearrangements in a Latin American cohort of chronic lymphocytic leukemia patients","authors":"Carmen Stanganelli, Juana Cabrera, Andrea Bender, Evangelina Agriello, Davi Coe Torres, Gerson Moura Ferreira, Maria Paula Mota dos Santos, Eliana Saul Furquim Werneck Abdelhay, Irma Slavutsky","doi":"10.1016/j.leukres.2025.108151","DOIUrl":"10.1016/j.leukres.2025.108151","url":null,"abstract":"","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"160 ","pages":"Article 108151"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145827879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01Epub Date: 2025-10-10DOI: 10.1016/j.leukres.2025.108119
Juan Li , Shulan Shi , Kefu Zhu , Linyang Zhe , Tianle Lu , Quanzhen Deng , Qingfang Li , Qiuling Hou , Tilong Huang , Qiangming Sun , Ming Yu , Hongchao Jiang
Background
Our previous findings indicate Semaphorin 4D (Sema4D) as a potential pediatric leukemia biomarker, promoting leukemogenesis via PI3K/AKT and ERK pathways, but its upstream regulatory mechanisms remain unclear. This study was conducted to explore the potential regulatory relationship between Insulin growth factor 2 mRNA binding protein 3 (IGF2BP3) and Sema4D in acute myeloid leukemia (AML).
Methods
The expression levels of Sema4D and IGF2BP3 were analyzed in PBMCs from 41 newly diagnosed patients with pediatric acute myeloid leukemia (AML) and 35 healthy pediatric donors who presented no history of leukemia using western blotting and qRT-PCR. IGF2BP3 overexpression and knockdown models were established in Kasumi-1 and HL-60 cells via lentiviral infection. Cell proliferation, apoptosis, and cell cycle distribution were assessed using CCK-8 and flow cytometry. The stability of Sema4D mRNA and m6A methylation levels were evaluated via mRNA stability assay and qPCR.
Results
This study discovered that Sema4D and IGF2BP3 were overexpressed in the peripheral blood mononuclear cells (PBMCs) of AML patients, and their expression levels were positively correlated. IGF2BP3 overexpression enhanced cell proliferation and cell cycle progression, and inhibited apoptosis in AML cells, while knockdown had the opposite effect. Mechanistic exploration revealed that IGF2BP3 enhances the stability of Sema4D mRNA through m6A-dependent mechanisms.
Conclusion
In this study, we demonstrate that the IGF2BP3/Sema4D axis is a crucial regulator in AML development, driving cell proliferation and survival through post-transcriptional regulation of Sema4D by IGF2BP3 in an m6A-dependent manner. Our findings highlight the potential of targeting this axis as a therapeutic strategy for AML treatment.
{"title":"IGF2BP3 promotes acute myeloid leukemia cell progression by regulating Semaphorin 4D stability in an m6A-dependent manner","authors":"Juan Li , Shulan Shi , Kefu Zhu , Linyang Zhe , Tianle Lu , Quanzhen Deng , Qingfang Li , Qiuling Hou , Tilong Huang , Qiangming Sun , Ming Yu , Hongchao Jiang","doi":"10.1016/j.leukres.2025.108119","DOIUrl":"10.1016/j.leukres.2025.108119","url":null,"abstract":"<div><h3>Background</h3><div>Our previous findings indicate Semaphorin 4D (Sema4D) as a potential pediatric leukemia biomarker, promoting leukemogenesis via PI3K/AKT and ERK pathways, but its upstream regulatory mechanisms remain unclear. This study was conducted to explore the potential regulatory relationship between Insulin growth factor 2 mRNA binding protein 3 (IGF2BP3) and Sema4D in acute myeloid leukemia (AML).</div></div><div><h3>Methods</h3><div>The expression levels of Sema4D and IGF2BP3 were analyzed in PBMCs from 41 newly diagnosed patients with pediatric acute myeloid leukemia (AML) and 35 healthy pediatric donors who presented no history of leukemia using western blotting and qRT-PCR. IGF2BP3 overexpression and knockdown models were established in Kasumi-1 and HL-60 cells via lentiviral infection. Cell proliferation, apoptosis, and cell cycle distribution were assessed using CCK-8 and flow cytometry. The stability of Sema4D mRNA and m6A methylation levels were evaluated via mRNA stability assay and qPCR.</div></div><div><h3>Results</h3><div>This study discovered that Sema4D and IGF2BP3 were overexpressed in the peripheral blood mononuclear cells (PBMCs) of AML patients, and their expression levels were positively correlated. IGF2BP3 overexpression enhanced cell proliferation and cell cycle progression, and inhibited apoptosis in AML cells, while knockdown had the opposite effect. Mechanistic exploration revealed that IGF2BP3 enhances the stability of Sema4D mRNA through m6A-dependent mechanisms.</div></div><div><h3>Conclusion</h3><div>In this study, we demonstrate that the IGF2BP3/Sema4D axis is a crucial regulator in AML development, driving cell proliferation and survival through post-transcriptional regulation of Sema4D by IGF2BP3 in an m6A-dependent manner. Our findings highlight the potential of targeting this axis as a therapeutic strategy for AML treatment.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"159 ","pages":"Article 108119"},"PeriodicalIF":2.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145445437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01Epub Date: 2025-10-12DOI: 10.1016/j.leukres.2025.108121
Yuanli Lei , Zhiting Tang , Jessica A. Reese , Omer Jamy , Mohamad Khawandanah , Manu Pandey , Muhammad Faisal , Adam Asch , Zimu Gong
Background
The current standard of care for acute myeloid leukemia (AML) patients undergoing intensive induction chemotherapy includes an interim bone marrow biopsy around day 14 (D14BM), and reinduction for patients with more than 5 % residual blasts on D14BM (Positive D14BM). However, this approach has become increasingly controversial. This systematic review and meta-analysis assess the sensitivity, specificity, and predictive value of D14BM in patients treated with one cycle of induction chemotherapy and evaluate the efficacy of reinduction versus observation in patients with Positive D14BM.
Methods
A systematic literature search was conducted using PubMed, Embase, Web of Science, and Cochrane databases. A bivariate model was used for pooled sensitivity and specificity. The positive predictive value was estimated based on pooled mean sensitivity, specificity, and historical refractory leukemia prevalence. Risk ratios (RR) for complete remission (CR) were meta-analyzed to compare reinduction versus observation in Positive D14BM patients.
Result
Among 1044 identified articles, 12 met inclusion criteria. Ten studies (1683 patients) evaluated the predictive value of D14BM, with a sensitivity of 49.7 % (proportion of refractory cases correctly identified by Positive D14BM) and specificity of 86.2 %. The estimated positive predictive value was 38.9 %, assuming a 15 % prevalence of true refractory leukemia. Eleven studies (832 patients) evaluated efficacy of reinduction, with a pooled RR of 1.00 (61 % vs. 60 %, 95 % CI: 0.76–1.31) for CR.
Conclusion
Positive D14BM has limited predictive power for refractory leukemia. Reinduction based on Positive D14BM does not improve CR rates compared to observation alone only and may expose patients to undue toxicity.
{"title":"The role of interim bone marrow assessments in acute myeloid leukemia – A systematic review and meta-analysis","authors":"Yuanli Lei , Zhiting Tang , Jessica A. Reese , Omer Jamy , Mohamad Khawandanah , Manu Pandey , Muhammad Faisal , Adam Asch , Zimu Gong","doi":"10.1016/j.leukres.2025.108121","DOIUrl":"10.1016/j.leukres.2025.108121","url":null,"abstract":"<div><h3>Background</h3><div>The current standard of care for acute myeloid leukemia (AML) patients undergoing intensive induction chemotherapy includes an interim bone marrow biopsy around day 14 (D14BM), and reinduction for patients with more than 5 % residual blasts on D14BM (Positive D14BM). However, this approach has become increasingly controversial. This systematic review and meta-analysis assess the sensitivity, specificity, and predictive value of D14BM in patients treated with one cycle of induction chemotherapy and evaluate the efficacy of reinduction versus observation in patients with Positive D14BM.</div></div><div><h3>Methods</h3><div>A systematic literature search was conducted using PubMed, Embase, Web of Science, and Cochrane databases. A bivariate model was used for pooled sensitivity and specificity. The positive predictive value was estimated based on pooled mean sensitivity, specificity, and historical refractory leukemia prevalence. Risk ratios (RR) for complete remission (CR) were meta-analyzed to compare reinduction versus observation in Positive D14BM patients.</div></div><div><h3>Result</h3><div>Among 1044 identified articles, 12 met inclusion criteria. Ten studies (1683 patients) evaluated the predictive value of D14BM, with a sensitivity of 49.7 % (proportion of refractory cases correctly identified by Positive D14BM) and specificity of 86.2 %. The estimated positive predictive value was 38.9 %, assuming a 15 % prevalence of true refractory leukemia. Eleven studies (832 patients) evaluated efficacy of reinduction, with a pooled RR of 1.00 (61 % vs. 60 %, 95 % CI: 0.76–1.31) for CR.</div></div><div><h3>Conclusion</h3><div>Positive D14BM has limited predictive power for refractory leukemia. Reinduction based on Positive D14BM does not improve CR rates compared to observation alone only and may expose patients to undue toxicity.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"159 ","pages":"Article 108121"},"PeriodicalIF":2.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145318432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01Epub Date: 2025-10-14DOI: 10.1016/j.leukres.2025.108117
Jennifer K. Lue , Priyanka J. Bobbili , Mahek Garg , Christopher W. Yee , Katherine E. Ryland , Sonia Gupta , Daisy Liu , Monika Raut , Mei Sheng Duh
Background
With the evolving treatment landscape and growing therapeutic options, it is essential to understand the treatments currently used in real-world clinical practice and the associated outcomes among patients with DLBCL to identify potential unmet treatment needs.
Patients and Methods
This retrospective longitudinal cohort study examined treatment patterns and outcomes for diffuse large B-cell lymphoma (DLBCL) patients using the COTA electronic health records database from 2016 to 2023. The study population included 3569 patients, treated in community oncology settings, who received first-line (1L) therapy.
Results
Nineteen percent of patients relapsed after 1L chemoimmunotherapy (primarily R-CHOP). The most common second-line treatments included rituximab-based regimens and autologous stem cell transplant (ASCT). Antibody-drug conjugates (ADCs) and CAR T-cell therapy were administered in third-line or later. Median progression-free survival (PFS) and overall survival (OS) decreased with each line. Relapsed/refractory real-world DLBCL patients experienced poor outcomes (24-month OS of 41.7 %). Patients receiving ASCT or CAR T-cell therapy had better OS than those who did not receive cellular therapies, with 24-month OS of 78 %, 54 %, and 31 %, respectively.
Conclusion
This study highlights the need for improved treatment options and increased access to novel therapies, emphasizing gaps in community oncology settings.
{"title":"Real-world treatment patterns and clinical outcomes of patients with treatment-naïve and relapsed/refractory diffuse large B-cell lymphoma in the United States","authors":"Jennifer K. Lue , Priyanka J. Bobbili , Mahek Garg , Christopher W. Yee , Katherine E. Ryland , Sonia Gupta , Daisy Liu , Monika Raut , Mei Sheng Duh","doi":"10.1016/j.leukres.2025.108117","DOIUrl":"10.1016/j.leukres.2025.108117","url":null,"abstract":"<div><h3>Background</h3><div>With the evolving treatment landscape and growing therapeutic options, it is essential to understand the treatments currently used in real-world clinical practice and the associated outcomes among patients with DLBCL to identify potential unmet treatment needs.</div></div><div><h3>Patients and Methods</h3><div>This retrospective longitudinal cohort study examined treatment patterns and outcomes for diffuse large B-cell lymphoma (DLBCL) patients using the COTA electronic health records database from 2016 to 2023. The study population included 3569 patients, treated in community oncology settings, who received first-line (1L) therapy.</div></div><div><h3>Results</h3><div>Nineteen percent of patients relapsed after 1L chemoimmunotherapy (primarily R-CHOP). The most common second-line treatments included rituximab-based regimens and autologous stem cell transplant (ASCT). Antibody-drug conjugates (ADCs) and CAR T-cell therapy were administered in third-line or later. Median progression-free survival (PFS) and overall survival (OS) decreased with each line. Relapsed/refractory real-world DLBCL patients experienced poor outcomes (24-month OS of 41.7 %). Patients receiving ASCT or CAR T-cell therapy had better OS than those who did not receive cellular therapies, with 24-month OS of 78 %, 54 %, and 31 %, respectively.</div></div><div><h3>Conclusion</h3><div>This study highlights the need for improved treatment options and increased access to novel therapies, emphasizing gaps in community oncology settings.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"159 ","pages":"Article 108117"},"PeriodicalIF":2.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145517199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}